Royalty Pharma plc (NASDAQ:RPRX – Get Rating) has been assigned an average rating of “Moderate Buy” from the eight ratings firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $54.14.
RPRX has been the topic of a number of analyst reports. Citigroup increased their price target on Royalty Pharma from $50.00 to $60.00 in a research note on Thursday, July 28th. StockNews.com began coverage on shares of Royalty Pharma in a research note on Wednesday, October 12th. They issued a “hold” rating on the stock. Morgan Stanley boosted their target price on shares of Royalty Pharma from $51.00 to $54.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 9th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Royalty Pharma from $50.00 to $52.00 and gave the company an “overweight” rating in a report on Tuesday, October 18th.
Insider Activity at Royalty Pharma
In other news, Director Mario Germano Giuliani sold 261,881 shares of the business’s stock in a transaction on Wednesday, September 7th. The shares were sold at an average price of $42.66, for a total value of $11,171,843.46. Following the transaction, the director now owns 8,814,759 shares of the company’s stock, valued at $376,037,618.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Mario Germano Giuliani sold 261,881 shares of the company’s stock in a transaction dated Wednesday, September 7th. The shares were sold at an average price of $42.66, for a total value of $11,171,843.46. Following the completion of the sale, the director now directly owns 8,814,759 shares of the company’s stock, valued at $376,037,618.94. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder 1978 Sicaf Sif S.A. – Gg St Gg sold 250,000 shares of the stock in a transaction that occurred on Wednesday, September 7th. The shares were sold at an average price of $42.53, for a total transaction of $10,632,500.00. Following the completion of the transaction, the insider now directly owns 22,674,176 shares of the company’s stock, valued at $964,332,705.28. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,887,623 shares of company stock worth $79,272,782. 24.86% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Royalty Pharma Price Performance
NASDAQ RPRX opened at $42.93 on Friday. Royalty Pharma has a twelve month low of $36.15 and a twelve month high of $44.75. The company has a debt-to-equity ratio of 0.59, a quick ratio of 2.07 and a current ratio of 2.07. The stock has a market capitalization of $26.07 billion, a PE ratio of 51.11, a P/E/G ratio of 1.06 and a beta of 0.34. The stock has a 50-day simple moving average of $41.74 and a 200 day simple moving average of $41.85.
Royalty Pharma Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 15th. Shareholders of record on Friday, November 18th will be paid a dividend of $0.19 per share. The ex-dividend date is Thursday, November 17th. This represents a $0.76 dividend on an annualized basis and a yield of 1.77%. Royalty Pharma’s dividend payout ratio is currently 90.48%.
About Royalty Pharma
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
- Get a free copy of the StockNews.com research report on Royalty Pharma (RPRX)
- Is the 60/40 Portfolio Mix Still in Vogue?
- Three CBD Stocks to Dominate a Budding Industry
- Institutional Support for Analog Devices Remains High
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.